These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 26608955

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [Abstract] [Full Text] [Related]

  • 4. In Vitro and In Vivo Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated In Vitro Selection.
    Lloren KKS, Kwon JJ, Choi WS, Jeong JH, Ahn SJ, Choi YK, Baek YH, Song MS.
    J Virol; 2019 Mar 15; 93(6):. PubMed ID: 30602610
    [Abstract] [Full Text] [Related]

  • 5. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
    Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.
    Antimicrob Agents Chemother; 2013 Dec 15; 57(12):6141-6. PubMed ID: 24080660
    [Abstract] [Full Text] [Related]

  • 6. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
    Choi WS, Jeong JH, Kwon JJ, Ahn SJ, Lloren KKS, Kwon HI, Chae HB, Hwang J, Kim MH, Kim CJ, Webby RJ, Govorkova EA, Choi YK, Baek YH, Song MS.
    J Virol; 2018 Jan 01; 92(1):. PubMed ID: 29046464
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.
    Antivir Ther; 2010 Jan 01; 15(8):1151-9. PubMed ID: 21149922
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
    Fujisaki S, Imai M, Takashita E, Taniwaki T, Xu H, Kishida N, Yokoyama M, Sato H, Tashiro M, Odagiri T.
    J Infect Chemother; 2013 Oct 01; 19(5):891-5. PubMed ID: 23529501
    [Abstract] [Full Text] [Related]

  • 13. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2015 Jan 01; 21(1):39-42. PubMed ID: 25277670
    [Abstract] [Full Text] [Related]

  • 14. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y, Baz M, Boivin G.
    Antivir Ther; 2006 Jan 01; 11(8):971-6. PubMed ID: 17302366
    [Abstract] [Full Text] [Related]

  • 15. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.
    Antiviral Res; 2015 May 01; 117():27-38. PubMed ID: 25721488
    [Abstract] [Full Text] [Related]

  • 16. Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.
    Zaraket H, Dapat C, Ghanem S, Ali Z, Lteif M, Kondo H, Dapat IC, Saito K, Kayali G, Suzuki H, Dbaibo G, Saito R.
    Intervirology; 2014 May 01; 57(6):344-52. PubMed ID: 25301400
    [Abstract] [Full Text] [Related]

  • 17. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.
    Biochem Biophys Res Commun; 2012 Dec 07; 429(1-2):51-6. PubMed ID: 23131559
    [Abstract] [Full Text] [Related]

  • 18. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.
    Duwe S, Schweiger B.
    J Virol Methods; 2008 Nov 07; 153(2):134-41. PubMed ID: 18725246
    [Abstract] [Full Text] [Related]

  • 19. Low antiviral resistance in Influenza A and B viruses isolated in Mexico from 2010 to 2023.
    Franco-May DA, Gómez-Carballo J, Barrera-Badillo G, Cruz-Ortíz MN, Núñez-García TE, Arellano-Suárez DS, Wong-Arámbula C, López-Martínez I, Wong-Chew RM, Ayora-Talavera G.
    Antiviral Res; 2024 Jul 07; 227():105918. PubMed ID: 38795911
    [Abstract] [Full Text] [Related]

  • 20. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL.
    J Antimicrob Chemother; 2006 Oct 07; 58(4):723-32. PubMed ID: 16891631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.